| 000 | 01803 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516134319.0 | ||
| 264 | 0 | _c20140113 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1473-5687 | ||
| 024 | 7 |
_a10.1097/MEG.0b013e32835ee516 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Ye | |
| 245 | 0 | 0 |
_aTelbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. _h[electronic resource] |
| 260 |
_bEuropean journal of gastroenterology & hepatology _cJul 2013 |
||
| 300 |
_a814-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenine _xadverse effects |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aChi-Square Distribution |
| 650 | 0 | 4 |
_aDNA, Viral _xblood |
| 650 | 0 | 4 |
_aDrug Resistance, Viral _xgenetics |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOrganophosphonates _xadverse effects |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aTelbivudine |
| 650 | 0 | 4 |
_aThymidine _xadverse effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 |
_aVirus Replication _xdrug effects |
| 700 | 1 | _aLian, Jian-Qi | |
| 700 | 1 | _aLi, Yu | |
| 700 | 1 | _aWang, Jie-Pin | |
| 700 | 1 | _aHuang, Chang-Xing | |
| 700 | 1 | _aBai, Xue-Fan | |
| 700 | 1 | _aWang, Jiu-Ping | |
| 773 | 0 |
_tEuropean journal of gastroenterology & hepatology _gvol. 25 _gno. 7 _gp. 814-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MEG.0b013e32835ee516 _zAvailable from publisher's website |
| 999 |
_c22501844 _d22501844 |
||